x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Chung, Wendy KRemove Chung, Wendy K filter
- Klein, Teri ERemove Klein, Teri E filter
Publication Date
Please choose a date range between 2017 and 2022.
Author
- Miller, David T3
- Adelman, Kathy2
- Amendola, Laura M2
- Bale, Sherri J2
- Gollob, Michael H2
- Gordon, Adam S2
- Harrison, Steven M2
- Herman, Gail E2
- Hershberger, Ray E2
- Lee, Kristy2
- Martin, Christa Lese2
- Richards, C Sue2
- Stewart, Douglas R2
- Vlangos, Christopher N2
- Abul-Husn, Noura S1
- Brothers, Kyle1
- Eng, Christine1
- Evans, James P1
- Hufnagel, Sophia B1
- Kalia, Sarah S1
- Korf, Bruce R1
- Martin, Christa L1
- McKelvey, Kent1
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
3 Results
- ACMG Statement
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 24Issue 7p1407–1414Published online: June 17, 2022- David T. Miller
- Kristy Lee
- Noura S. Abul-Husn
- Laura M. Amendola
- Kyle Brothers
- Wendy K. Chung
- and others
Cited in Scopus: 13The American College of Medical Genetics and Genomics (ACMG) previously published guidance for reporting secondary findings (SF) in the context of clinical exome and genome sequencing in 2013, 2017, and 2021.1-3 The ACMG Secondary Findings Working Group (SFWG) and Board of Directors (BOD) have agreed that the list of recommended genes should now be updated annually, but with an ongoing goal of maintaining this as a minimum list. Reporting of SF should be considered neither a replacement for indication-based diagnostic clinical genetic testing nor a form of population screening. - ACMG StatementOpen Archive
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 23Issue 8p1381–1390Published in issue: August, 2021- David T. Miller
- Kristy Lee
- Wendy K. Chung
- Adam S. Gordon
- Gail E. Herman
- Teri E. Klein
- and others
Cited in Scopus: 175A correction to this article is available online at https://doi.org/10.1038/s41436-021-01278-8 . - ACMG StatementOpen Archive
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
Genetics in MedicineVol. 19Issue 2p249–255Published in issue: February, 2017- Sarah S. Kalia
- Kathy Adelman
- Sherri J. Bale
- Wendy K. Chung
- Christine Eng
- James P. Evans
- and others
Cited in Scopus: 1117Disclaimer: These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical services. Adherence to these recommendations is completely voluntary and does not necessarily assure a successful medical outcome. These recommendations should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed toward obtaining the same results.